Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BBIO

BridgeBio Pharma Inc

Feb 13 • 04:00PM ET

75.25

-0.81 -1.06 %

Healthcare • Biotechnology • USA • NASD

Feb 12, 7:36 AMBridgeBio Pharma announces positive Phase 3 topline PROPEL 3 results for oral infigratinib in achondroplasia and plans NDA and MAA submissions in the second half of 2026

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI VB IWM VBK VXF XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.19	Insider Own	14.53%	Shs Outstand	192.63M	Perf Week	10.58%
Market Cap	14.50B	Forward P/E	-	EPS next Y	-1.55	Insider Trans	-3.80%	Shs Float	164.71M	Perf Month	-3.40%
Enterprise Value	16.57B	PEG	-	EPS next Q	-0.71	Inst Own	88.48%	Short Float	12.13%	Perf Quarter	13.64%
Income	-797.12M	P/S	40.99	EPS this Y	-19.48%	Inst Trans	0.97%	Short Ratio	7.80	Perf Half Y	47.03%
Sales	353.78M	P/B	-	EPS next Y	54.88%	ROA	-95.85%	Short Interest	19.98M	Perf YTD	-1.62%
Book/sh	-10.03	P/C	22.45	EPS next 5Y	-	ROE	-	52W High	84.94 -11.41%	Perf Year	138.43%
Cash/sh	3.35	P/FCF	-	EPS past 3/5Y	9.60% -3.04%	ROIC	-105.23%	52W Low	28.33 165.67%	Perf 3Y	549.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.10% 40.48%	Gross Margin	95.00%	Volatility	6.67% 5.40%	Perf 5Y	11.71%
Dividend TTM	-	EV/Sales	46.84	EPS Y/Y TTM	-73.59%	Oper. Margin	-168.17%	ATR (14)	4.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.76	Sales Y/Y TTM	62.46%	Profit Margin	-225.31%	RSI (14)	50.93	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	3.88	EPS Q/Q	-10.81%	SMA20	-0.44%	Beta	1.10	Target Price	97.95
Payout	-	Debt/Eq	-	Sales Q/Q	4318.01%	SMA50	-0.23%	Rel Volume	1.10	Prev Close	76.06
Employees	730	LT Debt/Eq	-	Earnings	Oct 29 AMC	SMA200	34.70%	Avg Volume	2.56M	Price	75.25
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.25% 13.24%	Trades		Volume	2,818,629	Change	-1.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$157
Jan-06-26	Initiated	Morgan Stanley	Overweight	$96
Dec-11-25	Initiated	Bernstein	Outperform	$94
Jul-30-25	Resumed	Raymond James	Outperform	$56
Jul-21-25	Initiated	Truist	Buy	$66
Jul-14-25	Initiated	Jefferies	Buy	$70
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform	$60
Jun-17-25	Initiated	Wolfe Research	Outperform	$49
Mar-31-25	Initiated	Redburn Atlantic	Buy	$50
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40

Show Previous Ratings

Feb-12-26 07:33AM	BridgeBio Unveils Positive Results For Its Most 'Hotly Debated' Phase 3 Drug (Investor's Business Daily)
03:47PM	BridgeBio Pharma shares rise on compelling Phase 3 trial results for achondroplasia drug (Proactive)
12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
10:00AM	BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
09:16AM	BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia (MarketBeat)
07:30AM	Loading…
07:30AM	BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia (GlobeNewswire)
02:30AM	BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis (BioPharma Dive)
Feb-09-26 02:44PM	Buy the Dip on This Biotech Stock After Recent Fall (Schaeffer's Research) +6.23%
03:26AM	BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Feb-06-26 02:20AM	BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed (Insider Monkey) +6.78%
Jan-27-26 05:10PM	CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-23-26 07:40AM	Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO) (Insider Monkey)
Jan-20-26 04:57AM	Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results (Insider Monkey)
Jan-16-26 01:00AM	BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 (GlobeNewswire)
04:01PM	Loading…
Jan-14-26 04:01PM	BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 (GlobeNewswire)
Jan-13-26 12:02AM	BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference (MarketBeat)
Jan-12-26 10:30AM	BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
10:18AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
Jan-09-26 10:18AM	BridgeBio Pharma Investor Update: PROPEL 3 Last Visit Set as Infigratinib Phase 3 Readout Nears (MarketBeat)
Jan-05-26 07:30AM	BridgeBio to Participate in the J.P. Morgan Healthcare Conference (GlobeNewswire) -6.15%
Jan-02-26 07:30AM	BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET (GlobeNewswire)
Dec-22-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 09:39AM	PayPal downgraded, Roku upgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Here Are Thursdays Top Wall Street Analyst Research Calls: American Eagle Outfitters, Ferrari, Intuitive Surgical, Roku, PayPal, Synopsis, Visa, and More (24/7 Wall St.)
09:17AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
Dec-10-25 12:00PM	This Hot Biotech Stock Just Set New All-Time Highs (Barchart)
Dec-02-25 08:02AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Dec-01-25 07:30AM	Should You Grab This Strong Buy Growth Stock With 56% Upside? (Barchart)
Nov-25-25 07:30AM	BridgeBio to Participate in December Investor Conferences (GlobeNewswire)
03:29PM	Loading…
Nov-24-25 03:29PM	Biotech Stock Could Turn 4-Year Peak Into Records (Schaeffer's Research)
Nov-19-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-25 10:41AM	Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations (GlobeNewswire)
Nov-04-25 08:09PM	BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com)
07:30AM	BridgeBio to Participate in November Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 07:20PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 05:15PM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:28PM	BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High (Investor's Business Daily)
04:14PM	BridgeBio Pharma: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
07:00AM	BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 (GlobeNewswire)
03:55AM	BridgeBio chalks up another win for its rare disease research (BioPharma Dive)
Oct-28-25 04:01PM	BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th (GlobeNewswire)
09:14AM	BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock? (Zacks)
05:26AM	BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result (Insider Monkey)
Oct-27-25 01:18PM	BridgeBios stock up as muscular dystrophy therapy meets Phase III endpoints (Clinical Trials Arena) +17.14%
07:00AM	BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study (GlobeNewswire)
04:02AM	BridgeBio to seek approval of limb-girdle drug following new study data (BioPharma Dive)
Oct-24-25 04:01PM	BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week (GlobeNewswire)
Oct-13-25 12:47PM	This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year (Investor's Business Daily)
Oct-03-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 04:55PM	UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch (Insider Monkey)
09:46AM	BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics (Insider Monkey)
Oct-01-25 06:58PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
11:05AM	Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? (Zacks)
Sep-29-25 04:24PM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
10:42AM	BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition (Benzinga)
Sep-28-25 11:20AM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
11:15AM	Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM (GlobeNewswire)
Sep-24-25 02:12AM	H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) (Insider Monkey)
01:58AM	BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism (Insider Monkey)
Sep-22-25 07:30AM	BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 (GlobeNewswire)
Sep-10-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-25 10:15AM	Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? (Zacks)
Sep-06-25 02:30PM	Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Sep-05-25 07:00PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Sep-03-25 07:30AM	BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET (GlobeNewswire)
Sep-02-25 07:03PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:30AM	BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Aug-30-25 07:15AM	Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension (GlobeNewswire)
Aug-28-25 11:49PM	Here's What Wall Street Thinks About BridgeBio Pharma (BBIO) (Insider Monkey) +6.01%
06:48PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
10:10AM	Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? (Zacks)
Aug-27-25 07:30AM	BridgeBio to Participate in September Investor Conferences (GlobeNewswire)
Aug-25-25 07:30AM	BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 (GlobeNewswire)
Aug-20-25 12:34AM	TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales (Insider Monkey)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
Aug-06-25 02:18PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -8.94%
07:33AM	Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics (GlobeNewswire)
07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
03:29AM	BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... (GuruFocus.com)
Aug-05-25 05:25PM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:26PM	BridgeBio Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-04-25 09:22AM	BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-30-25 12:37PM	Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. (Barrons.com)
09:40AM	Peloton upgraded, Booking downgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:00AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-25-25 11:29PM	Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT (Insider Monkey)
Jul-24-25 11:47PM	Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy (Insider Monkey)
Jul-23-25 07:30AM	Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 (GlobeNewswire)
Jul-22-25 07:30AM	BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET (GlobeNewswire)
Jul-16-25 06:17AM	These 2 Momentum Stocks Got a Bullish Nod Heres Why They Could Reach New Highs (TipRanks)
Jul-14-25 09:32AM	Rivian downgraded, PayPal upgraded: Wall Street's top analyst calls (The Fly)
Jul-09-25 09:39AM	Microsoft upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly) +6.46%
Jul-06-25 04:00AM	BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA (Insider Monkey)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kumar Neil	Chief Executive Officer	Feb 10 '26	Sale	71.94	40,000	2,877,580	695,686	Feb 12 04:39 PM
Kumar Neil	Chief Executive Officer	Feb 11 '26	Sale	71.78	40,000	2,871,087	675,686	Feb 12 04:39 PM
Kumar Neil	Chief Executive Officer	Jan 09 '26	Sale	77.11	40,000	3,084,313	715,686	Jan 12 09:01 PM
Kumar Neil	Chief Executive Officer	Jan 08 '26	Sale	73.97	40,000	2,958,855	735,686	Jan 12 09:01 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 08 '26	Proposed Sale	74.27	120,000	8,912,400		Jan 08 04:23 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jan 08 '26	Proposed Sale	74.27	100,000	7,427,000		Jan 08 04:23 PM
Kumar Neil	Chief Executive Officer	Dec 15 '25	Sale	74.64	30,011	2,239,902	228,776	Dec 16 06:27 PM
NEIL KUMAR	Director	Dec 15 '25	Proposed Sale	75.15	30,011	2,255,327		Dec 15 04:23 PM
Apuli Maricel	Chief Accounting Officer	Dec 08 '25	Sale	74.26	2,000	148,520	130,297	Dec 10 07:53 AM
Kumar Neil	Chief Executive Officer	Dec 04 '25	Sale	74.40	40,000	2,975,913	775,686	Dec 08 05:54 PM
Kumar Neil	Chief Executive Officer	Dec 05 '25	Sale	73.31	40,000	2,932,563	755,686	Dec 08 05:54 PM
Kumar Neil	Chief Executive Officer	Nov 20 '25	Sale	65.84	26,156	1,722,224	228,776	Nov 24 06:46 PM
NEIL KUMAR	Director	Nov 20 '25	Proposed Sale	65.54	26,156	1,714,264		Nov 20 04:20 PM
Lo Andrew	Director	Nov 18 '25	Sale	65.69	55,000	3,613,069	50,583	Nov 19 05:08 PM
Lo Andrew	Director	Nov 17 '25	Sale	66.67	40,599	2,706,593	14,089	Nov 19 05:08 PM
Scott Randal W.	Director	Nov 17 '25	Option Exercise	16.75	10,000	167,500	21,589	Nov 19 05:06 PM
Scott Randal W.	Director	Nov 17 '25	Sale	66.65	10,000	666,465	11,589	Nov 19 05:06 PM
Trimarchi Thomas	President and CFO	Nov 17 '25	Sale	66.46	16,934	1,125,404	382,830	Nov 18 07:28 PM
ANDREW W LO	Director	Nov 18 '25	Proposed Sale	65.69	55,000	3,613,066		Nov 18 04:06 PM
ANDREW W LO	Director	Nov 17 '25	Proposed Sale	66.67	40,599	2,706,589		Nov 17 05:24 PM
RANDAL SCOTT	Director	Nov 17 '25	Proposed Sale	66.39	10,000	663,900		Nov 17 04:27 PM
THOMAS TRIMARCHI	Officer	Nov 17 '25	Proposed Sale	66.46	16,934	1,125,403		Nov 17 04:11 PM
Valantine Hannah	Director	Nov 12 '25	Option Exercise	48.45	25,484	1,234,700	32,949	Nov 14 04:50 PM
Valantine Hannah	Director	Nov 12 '25	Sale	66.07	25,484	1,683,728	7,465	Nov 14 04:50 PM
Hannah A Valantine	Director	Nov 12 '25	Proposed Sale	66.07	25,484	1,683,728		Nov 12 04:04 PM
Kumar Neil	Chief Executive Officer	Nov 06 '25	Sale	63.15	40,000	2,526,117	815,686	Nov 10 05:33 PM
Kumar Neil	Chief Executive Officer	Nov 07 '25	Sale	61.42	40,000	2,456,994	795,686	Nov 10 05:33 PM
DANIELS RONALD J	Director	Nov 06 '25	Option Exercise	34.65	61,031	2,114,724	78,022	Nov 07 06:03 PM
DANIELS RONALD J	Director	Nov 06 '25	Sale	63.72	61,031	3,888,999	16,991	Nov 07 06:03 PM
RONALD J DANIELS	Director	Nov 06 '25	Proposed Sale	63.72	61,031	3,888,999		Nov 06 04:54 PM
MCCORMICK FRANK	Director	Oct 29 '25	Sale	66.58	198,359	13,206,528	679,979	Oct 31 04:38 PM
Frank McCormick	Director	Oct 29 '25	Proposed Sale	66.58	198,359	13,206,532		Oct 29 05:59 PM
MCCORMICK FRANK	Director	Oct 27 '25	Sale	65.00	1,641	106,665	878,338	Oct 29 05:10 PM
Frank McCormick	Director	Oct 27 '25	Proposed Sale	65.00	1,641	106,665		Oct 27 04:06 PM
Kumar Neil	Chief Executive Officer	Oct 09 '25	Sale	54.80	40,000	2,192,092	835,686	Oct 10 05:40 PM
Kumar Neil	Chief Executive Officer	Oct 08 '25	Sale	54.78	40,000	2,191,350	855,686	Oct 10 05:40 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Oct 08 '25	Proposed Sale	54.22	120,000	6,506,400		Oct 08 04:18 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Oct 08 '25	Proposed Sale	54.22	120,000	6,506,400		Oct 08 04:17 PM
MCCORMICK FRANK	Director	Sep 05 '25	Option Exercise	11.92	74,000	882,080	157,275	Sep 08 06:06 PM
MCCORMICK FRANK	Director	Sep 05 '25	Sale	53.16	74,000	3,933,544	83,275	Sep 08 06:06 PM
Kumar Neil	Chief Executive Officer	Sep 05 '25	Sale	53.05	40,000	2,122,047	875,686	Sep 08 06:05 PM
Kumar Neil	Chief Executive Officer	Sep 04 '25	Sale	51.34	40,000	2,053,788	895,686	Sep 08 06:05 PM
FRANK P. MCCORMICK	Director	Sep 05 '25	Proposed Sale	53.14	74,000	3,932,057		Sep 05 04:46 PM
Trimarchi Thomas	President and CFO	Aug 21 '25	Sale	49.48	42,237	2,090,081	421,081	Aug 22 04:58 PM
Kumar Neil	Chief Executive Officer	Aug 20 '25	Sale	48.82	26,156	1,276,927	223,090	Aug 22 04:46 PM
THOMAS TRIMARCHI	Officer	Aug 21 '25	Proposed Sale	49.48	42,237	2,090,077		Aug 21 04:10 PM
NEIL KUMAR	Director	Aug 20 '25	Proposed Sale	48.91	26,156	1,279,290		Aug 20 04:23 PM
Trimarchi Thomas	President and CFO	Aug 18 '25	Sale	50.23	17,353	871,722	463,318	Aug 19 07:40 PM
THOMAS TRIMARCHI	Officer	Aug 18 '25	Proposed Sale	50.23	17,353	871,723		Aug 18 04:03 PM
HOMCY CHARLES J	Director	Aug 08 '25	Sale	46.05	250,000	11,512,443	966,674	Aug 12 07:06 PM
HOMCY CHARLES J	Director	Aug 11 '25	Sale	48.00	50,000	2,400,000	916,674	Aug 12 07:06 PM
Apuli Maricel	Chief Accounting Officer	Aug 07 '25	Sale	45.44	1,000	45,440	141,859	Aug 11 06:29 PM
Kumar Neil	Chief Executive Officer	Aug 08 '25	Sale	46.22	40,000	1,848,828	915,686	Aug 11 06:12 PM
Kumar Neil	Chief Executive Officer	Aug 07 '25	Sale	45.45	40,000	1,818,121	935,686	Aug 11 06:12 PM
CHARLES J HOMCY	Director	Aug 11 '25	Proposed Sale	48.00	50,000	2,400,000		Aug 11 04:17 PM
CHARLES J HOMCY	Director	Aug 08 '25	Proposed Sale	46.05	250,000	11,512,420		Aug 08 05:11 PM
Ellis Andrea	Director	Aug 05 '25	Option Exercise	16.75	17,167	287,547	35,756	Aug 07 04:50 PM
Ellis Andrea	Director	Aug 05 '25	Sale	49.00	17,167	841,183	18,589	Aug 07 04:50 PM
ANDREA ELLIS	Director	Aug 05 '25	Proposed Sale	49.00	17,167	841,183		Aug 05 04:26 PM
Kumar Neil	Chief Executive Officer	Jul 02 '25	Sale	42.73	40,000	1,709,050	955,686	Jul 03 04:30 PM
Kumar Neil	Chief Executive Officer	Jul 01 '25	Sale	42.54	40,000	1,701,400	975,686	Jul 03 04:30 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jun 27 '25	Sale	44.00	3,500,000	154,000,000	18,555,375	Jul 01 07:48 PM
KUMAR HALDEA REVOCABLETRUST U/	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,418	106,504	7,465	Jun 30 05:51 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,289	100,824	398	Jun 30 05:51 PM
MCCORMICK FRANK	Director	Jun 24 '25	Sale	44.23	100,000	4,422,800	879,979	Jun 26 05:08 PM
DENIS VON KAEPPLER IRA ROLLOVE	client's wife is a BoD	Jun 26 '25	Proposed Sale	44.03	1,891	83,261		Jun 26 04:19 PM
HANNAH VALANTINE & DENIS VON K	spouse of bod / bod is joint o	Jun 26 '25	Proposed Sale	44.01	1,542	67,863		Jun 26 04:16 PM
HANNAH A VALANTINE & DENIS VON	Officer	Jun 26 '25	Proposed Sale	44.11	876	38,640		Jun 26 04:14 PM
ERICKA VON KAEPPLER & DENIS VO	account owners are spouse and	Jun 26 '25	Proposed Sale	44.13	398	17,562		Jun 26 04:13 PM
MCCORMICK FRANK	Officer	Jun 24 '25	Proposed Sale	44.23	100,000	4,422,803		Jun 24 05:59 PM
Valantine Hannah	Director	Jun 10 '25	Option Exercise	16.75	4,292	71,891	6,056	Jun 11 05:00 PM
Valantine Hannah	Director	Jun 10 '25	Sale	40.00	4,292	171,680	1,764	Jun 11 05:00 PM
HANNAH A VALANTINE	Director	Jun 10 '25	Proposed Sale	40.00	4,292	171,680		Jun 10 04:01 PM
Kumar Neil	Chief Executive Officer	May 20 '25	Sale	33.40	75,000	2,504,978	4,798,447	May 20 06:06 PM
Kumar Neil	Chief Executive Officer	May 19 '25	Sale	33.33	26,156	871,764	217,404	May 20 06:06 PM
NEIL KUMAR	Director	May 19 '25	Proposed Sale	33.84	26,156	885,119		May 19 04:25 PM
KKR Genetic Disorder L.P.	10% Owner	May 12 '25	Sale	34.20	6,000,000	205,200,000	13,260,971	May 14 05:24 PM
KKR Genetic Disorder L.P.	Affiliate	May 12 '25	Proposed Sale	35.68	6,000,000	214,080,000		May 12 09:46 PM
Apuli Maricel	Chief Accounting Officer	May 02 '25	Sale	38.51	1,026	39,509	147,639	May 06 04:45 PM
Lo Andrew	Director	May 02 '25	Sale	38.50	100,000	3,849,900	105,583	May 06 04:42 PM
Lo Andrew	Director	May 02 '25	Proposed Sale	35.23	100,000	3,523,000		May 02 04:36 PM
Kumar Neil	Chief Executive Officer	Apr 22 '25	Sale	34.11	75,000	2,558,025	4,873,447	Apr 24 04:28 PM
Ellis Andrea	Director	Apr 14 '25	Option Exercise	8.45	10,000	84,500	22,000	Apr 16 05:39 PM
Ellis Andrea	Director	Apr 14 '25	Sale	35.00	10,000	350,000	12,000	Apr 16 05:39 PM
ANDREA ELLIS	Director	Apr 14 '25	Proposed Sale	35.00	10,000	350,000		Apr 14 04:21 PM
Ellis Andrea	Director	Apr 01 '25	Option Exercise	8.45	30,000	253,500	42,000	Apr 03 05:11 PM
Ellis Andrea	Director	Apr 01 '25	Sale	34.05	30,000	1,021,500	12,000	Apr 03 05:11 PM
ANDREA ELLIS	Director	Apr 01 '25	Proposed Sale	34.05	30,000	1,021,500		Apr 02 04:48 PM
Kumar Neil	Chief Executive Officer	Mar 25 '25	Sale	36.87	75,000	2,764,943	4,948,447	Mar 27 04:54 PM
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM

Open in Screener

CDNA

Caredx Inc

Feb 13 • 04:00PM ET

19.63

+0.53 2.77 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: NTRA ILMN FLGT GH EXAS TWST VRTX CRSP TXG QGEN

| Held by: ARKG XBI VTI IWM VXF IWO IBB VTWO SCHA JSMD

Index	RUT	P/E	16.46	EPS (ttm)	1.19	Insider Own	10.86%	Shs Outstand	51.41M	Perf Week	0.82%
Market Cap	1.01B	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-0.78%	Shs Float	45.84M	Perf Month	-3.40%
Enterprise Value	843.04M	PEG	-	EPS next Q	0.02	Inst Own	97.68%	Short Float	12.55%	Perf Quarter	20.36%
Income	70.45M	P/S	2.82	EPS this Y	-132.13%	Inst Trans	0.34%	Short Ratio	7.55	Perf Half Y	66.07%
Sales	358.00M	P/B	3.24	EPS next Y	96.21%	ROA	15.50%	Short Interest	5.75M	Perf YTD	4.19%
Book/sh	6.05	P/C	5.20	EPS next 5Y	-	ROE	24.11%	52W High	25.55 -23.17%	Perf Year	-20.97%
Cash/sh	3.78	P/FCF	27.22	EPS past 3/5Y	- -	ROIC	21.20%	52W Low	10.96 79.11%	Perf 3Y	30.35%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.04% 21.31%	Gross Margin	66.92%	Volatility	6.67% 5.47%	Perf 5Y	-78.04%
Dividend TTM	-	EV/Sales	2.35	EPS Y/Y TTM	148.22%	Oper. Margin	-7.01%	ATR (14)	1.15	Perf 10Y	284.90%
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	14.46%	Profit Margin	19.68%	RSI (14)	49.09	Recom	2.11
Dividend Gr. 3/5Y	- -	Current Ratio	3.03	EPS Q/Q	122.29%	SMA20	-2.50%	Beta	2.51	Target Price	24.00
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	20.72%	SMA50	-0.25%	Rel Volume	0.61	Prev Close	19.10
Employees	650	LT Debt/Eq	0.07	Earnings	Feb 24 AMC	SMA200	18.26%	Avg Volume	762.12K	Price	19.63
IPO	Jul 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	136.63% 4.91%	Trades		Volume	464,003	Change	2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-26	Downgrade	Craig Hallum	Buy → Hold	$26
Aug-26-25	Initiated	William Blair	Mkt Perform
Jan-15-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$28 → $24
Aug-28-24	Initiated	Wells Fargo	Underweight	$28
Aug-19-24	Upgrade	BTIG Research	Neutral → Buy	$40
May-13-24	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-24	Upgrade	Craig Hallum	Hold → Buy	$15
Nov-09-23	Upgrade	Stephens	Equal-Weight → Overweight	$10
Aug-15-23	Upgrade	Raymond James	Mkt Perform → Outperform	$12
May-11-23	Downgrade	BTIG Research	Buy → Neutral
Mar-07-23	Downgrade	Stephens	Overweight → Equal-Weight	$19 → $9
Mar-03-23	Downgrade	Raymond James	Strong Buy → Mkt Perform
Mar-03-23	Downgrade	Craig Hallum	Buy → Hold	$26 → $9
Apr-25-22	Initiated	Stephens	Overweight	$50
Jul-20-21	Resumed	BTIG Research	Buy	$115
Jun-03-21	Initiated	Goldman	Buy	$95
Feb-26-21	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-30-20	Reiterated	H.C. Wainwright	Buy	$47 → $55
Oct-08-20	Reiterated	H.C. Wainwright	Buy	$45 → $47
Oct-02-20	Reiterated	H.C. Wainwright	Buy	$40 → $45

Show Previous Ratings

Today 01:09AM	CareDx Expands Transplant Plus Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data (MarketBeat)
Feb-12-26 07:05AM	CareDx Announces Clinical Validation Results for AlloHeme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy (Business Wire)
Feb-10-26 04:01PM	CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (Business Wire)
Feb-03-26 07:05AM	CareDx to Present AlloHeme Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings (Business Wire)
Jan-27-26 04:05PM	CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
10:45AM	Loading…
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:30AM	Implied Volatility Surging for CareDx Stock Options (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks) +20.08%
07:05AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-07-26 07:05AM	CareDx and 10x Genomics to Launch ImmuneScape Program - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response (Business Wire)
Jan-06-26 10:48AM	Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now? (Zacks) -5.05%
Dec-26-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-23-25 09:15AM	Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-18-25 05:00PM	CareDx Provides Notice of Proposed Derivative Settlement (Business Wire)
Nov-27-25 09:55AM	Wall Street Analysts Believe CareDx (CDNA) Could Rally 28.02%: Here's is How to Trade (Zacks)
04:05PM	Loading…
Nov-24-25 04:05PM	SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation (Business Wire)
Nov-07-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.91%
Nov-06-25 08:00AM	CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025 (Business Wire) -9.20%
Nov-05-25 12:03AM	CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance (GuruFocus.com) +13.84%
Nov-04-25 07:00PM	CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:15PM	CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
05:12PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 07:52AM	CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 07:05AM	CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer (Business Wire)
Oct-23-25 04:05PM	CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure (Business Wire)
Oct-22-25 04:01PM	CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors (Business Wire)
Oct-21-25 08:00AM	CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-06-25 07:05AM	CareDx Announces New IVD Products and IVDR Certification for AlloSeq Tx and QTYPE at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting (Business Wire)
Sep-02-25 04:01PM	CareDx Issues Comment Letter on Draft LCD Policy (Business Wire) -8.09%
01:08PM	Loading…
Aug-26-25 01:08PM	CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential (Benzinga)
Aug-22-25 08:30AM	Do Options Traders Know Something About CareDx Stock We Don't? (Zacks)
Aug-21-25 04:01PM	CareDx to Participate in Wells Fargo Healthcare Conference (Business Wire)
Aug-12-25 08:00AM	Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire) +5.86%
Aug-06-25 06:30PM	Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings (Zacks) -7.86%
05:45PM	CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates (Zacks)
04:57PM	CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire)
04:43PM	CareDx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	CareDx Announces Second Quarter 2025 Financial Results (Business Wire)
12:56PM	CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation (Business Wire)
Aug-05-25 10:07AM	What To Expect From CareDx Inc (CDNA) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 04:01PM	CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress (Business Wire)
Jul-23-25 07:05AM	CareDx to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-22-25 07:06AM	CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains? (Zacks)
Jul-18-25 08:00AM	CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection (Business Wire)
Jun-03-25 04:30PM	CareDx Announces Repurchase of 5% of Outstanding Shares (Business Wire) +10.67%
May-13-25 04:01PM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-01-25 03:17AM	CareDx Inc (CDNA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments (GuruFocus.com) -10.72%
Apr-30-25 08:39PM	CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript (Seeking Alpha) -6.89%
05:50PM	CareDx (CDNA) Tops Q1 Earnings Estimates (Zacks)
04:50PM	CareDx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports First Quarter 2025 Results (Business Wire)
Apr-29-25 07:05AM	CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-24-25 07:05AM	CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-21-25 04:01PM	CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-08-25 07:05AM	CareDx to Report First Quarter 2025 Financial Results (Business Wire)
Apr-04-25 12:40PM	Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-11-25 07:05AM	CareDx Launches Two Expanded Indications for AlloSure Testing Services (Business Wire)
Feb-27-25 02:20AM	CareDx Inc (CDNA) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-26-25 07:00PM	CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:56PM	CareDx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-25-25 10:39AM	CareDx Inc (CDNA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:05AM	CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict (Business Wire)
Feb-20-25 07:05AM	CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients (Business Wire) -5.34%
Feb-13-25 07:05AM	CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies (Business Wire)
Feb-11-25 07:05AM	CareDx to Report Fourth Quarter and Full Year 2024 Financial Results (Business Wire) -8.43%
03:22AM	CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Feb-10-25 02:51PM	Trade Tracker: Amy Raskin trims Vertex, Natera & Kadant, buys CareDx and Impinj (CNBC TV) +11.16%
02:51PM	Final Trades: NRG Energy, MP Materials, CareDx and Applovin (CNBC TV)
Feb-05-25 09:55AM	Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect? (Zacks)
Jan-29-25 09:40AM	Is CareDx (CDNA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-28-25 08:19AM	CareDx (CDNA) Traded Down Due to Disappointing Quarterly Results (Insider Monkey)
Jan-24-25 08:35AM	Heres Why CareDx (CDNA) Traded Lower in Q4 (Insider Monkey)
Jan-15-25 03:50PM	Wells Fargo upgrades CareDx after a 30% pullback in stock (Investing.com)
Jan-14-25 03:43AM	Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength? (Zacks) -12.05%
Jan-13-25 07:00AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results (Business Wire) +6.09%
Jan-06-25 09:35AM	Implied Volatility Surging for CareDx (CDNA) Stock Options (Zacks)
Dec-18-24 07:05AM	CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.86%
Dec-11-24 07:00AM	TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (PR Newswire)
07:00AM	CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (Business Wire)
Dec-03-24 09:40AM	Has CareDx (CDNA) Outpaced Other Medical Stocks This Year? (Zacks)
Nov-29-24 10:46AM	Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA) (Insider Monkey)
Nov-25-24 09:55AM	Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know (Zacks)
Nov-15-24 09:35AM	After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA) (Zacks)
Nov-14-24 09:40AM	Are Medical Stocks Lagging CareDx (CDNA) This Year? (Zacks) -5.40%
Nov-12-24 07:05AM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-24 09:04AM	Accelerated Testing Volume Lifted CareDx (CDNA) in Q3 (Insider Monkey)
Nov-05-24 01:03PM	Q3 2024 CareDx Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Nov-04-24 05:03PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance (Business Wire)
Oct-23-24 07:00AM	CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology (Business Wire)
Oct-21-24 07:00AM	CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting (Business Wire)
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in CareDx Inc Holdings (GuruFocus.com) -6.49%
Oct-16-24 08:17AM	CareDx Reports Strong Q3 2024 Revenue Growth (TipRanks)
Oct-15-24 06:00AM	CareDx Reports Preliminary Financial Results for Third Quarter 2024 (Business Wire) -15.84%
Oct-11-24 04:30PM	CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 03:35PM	CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... (GuruFocus.com) -12.42%
07:05AM	CareDx Appoints Jing Huang Chief Data and AI Officer (Business Wire)

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novack Jeffrey Adam	Secretary and General Counsel	Feb 03 '26	Sale	20.56	4,441	91,286	125,364	Feb 04 04:22 PM
JEFFREY NOVACK	Officer	Feb 03 '26	Proposed Sale	20.42	4,441	90,685		Feb 03 04:33 PM
Hanna John Walter JR	President and CEO	Jan 22 '26	Sale	21.16	19,280	408,023	597,405	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 21 '26	Sale	21.00	200	4,200	616,685	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 15 '26	Sale	21.05	10,156	213,804	616,885	Jan 20 05:30 PM
JOHN HANNA	Director	Jan 15 '26	Proposed Sale	20.32	29,636	602,204		Jan 15 04:40 PM
Novack Jeffrey Adam	Secretary and General Counsel	Dec 04 '25	Sale	19.17	7,293	139,804	97,925	Dec 05 04:07 PM
JEFFREY NOVACK	Officer	Dec 04 '25	Proposed Sale	18.85	7,293	137,473		Dec 04 04:39 PM
Novack Jeffrey Adam	Secretary and General Counsel	Nov 07 '25	Sale	15.52	2,688	41,723	105,218	Nov 10 04:14 PM
Jeffrey Adam Novack	Officer	Nov 07 '25	Proposed Sale	15.01	2,688	40,347		Nov 07 04:37 PM
ABHISHEK JAIN	Officer	Nov 05 '25	Proposed Sale	15.77	53,388	842,050		Nov 05 04:21 PM
ABHISHEK JAIN	Officer	Oct 31 '25	Proposed Sale	14.90	9,964	148,464		Oct 31 04:48 PM
Bickerstaff George	Director	Sep 11 '25	Option Exercise	7.96	29,136	231,923	144,266	Sep 12 05:09 PM
Novack Jeffrey Adam	Secretary and General Counsel	Aug 05 '25	Sale	12.79	2,688	34,381	112,930	Aug 07 04:00 PM
Jeffrey Adam Novack	Officer	Aug 05 '25	Proposed Sale	12.60	2,688	33,869		Aug 05 04:27 PM
Maag Peter	Director	Jul 07 '25	Sale	18.58	10,000	185,831	308,846	Jul 10 04:04 PM
Valantine Hannah	Director	Jun 18 '25	Sale	19.16	10,570	202,566	38,994	Jun 23 04:30 PM
Maag Peter	Director	Jun 17 '25	Sale	19.24	10,000	192,420	318,846	Jun 20 04:30 PM
HANNAH VALANTINE	Director	Jun 18 '25	Proposed Sale	19.52	10,570	206,326		Jun 18 04:26 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Option Exercise	13.20	19,391	256,052	73,370	Jun 13 05:06 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Sale	19.90	19,391	385,918	53,979	Jun 13 05:06 PM
WILLIAM HAGSTROM	Director	Jun 11 '25	Proposed Sale	19.90	19,391	385,918		Jun 11 04:20 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Option Exercise	7.45	30,000	223,441	83,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Sale	17.45	30,000	523,413	53,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Proposed Sale	17.63	30,000	528,900		May 28 05:01 PM
COURNOYER CHRISTINE	Director	May 12 '25	Option Exercise	7.96	29,136	231,923	66,181	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Sale	15.96	29,136	465,022	37,045	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Proposed Sale	15.96	29,136	465,021		May 12 05:15 PM
Christine M. Cournoyer	Director	May 12 '25	Proposed Sale	15.36	12,000	184,320		May 12 05:10 PM
COURNOYER CHRISTINE	Director	May 06 '25	Sale	14.13	16,700	235,929	37,045	May 08 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	May 05 '25	Sale	14.70	2,688	39,514	121,350	May 07 04:38 PM
Christine M. Cournoyer	Director	May 06 '25	Proposed Sale	15.17	16,700	253,339		May 06 05:00 PM
Jeffrey Adam Novack	Officer	May 05 '25	Proposed Sale	15.00	2,688	40,320		May 05 04:39 PM
Maag Peter	Director	Apr 30 '25	Sale	17.23	13,281	228,796	316,743	May 02 04:49 PM
PETER MAAG	Director	Apr 30 '25	Proposed Sale	18.13	33,281	603,385		Apr 30 04:18 PM
Jain Abhishek	Chief Financial Officer	Apr 07 '25	Sale	17.72	265	4,696	337,418	Apr 09 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	Apr 07 '25	Sale	17.72	924	16,373	126,911	Apr 09 04:30 PM
Bickerstaff George	Director	Mar 10 '25	Sale	18.36	20,000	367,102	103,027	Mar 12 04:30 PM
GEORGE W BICKERSTAFF	Director	Mar 10 '25	Proposed Sale	18.36	20,000	367,102		Mar 10 05:03 PM

BBIO

BridgeBio Pharma Inc

CDNA

Caredx Inc

Upgrade your FINVIZ experience